Singapore markets closed

QuidelOrtho Corporation (QDEL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
41.45-0.72 (-1.71%)
At close: 04:00PM EDT
41.98 +0.53 (+1.28%)
After hours: 04:46PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close42.17
Open42.20
Bid41.39 x 100
Ask41.47 x 200
Day's range41.23 - 42.45
52-week range41.23 - 95.02
Volume534,292
Avg. volume1,088,148
Market cap2.772B
Beta (5Y monthly)0.12
PE ratio (TTM)N/A
EPS (TTM)-0.15
Earnings date04 May 2024 - 08 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est82.60
  • Business Wire

    QuidelOrtho Adds Fentanyl Test to Its Vitros® Systems as a MicroTip® Partnership Assay

    SAN DIEGO, April 10, 2024--QuidelOrtho Corporation (Nasdaq: QDEL) has added the ARK™ Fentanyl II Assay to its U.S. Vitros® XT 7600 and 5600 Integrated Systems as well as its Vitros® 4600 Chemistry System menu of assays as a MicroTip® Partnership Assay ("MPA"). This Fentanyl assay will help hospital and emergency room customers respond to the critical demand for enhanced opioid testing, allowing on-site fentanyl testing in less than 10 minutes to aid in immediate clinical decisions.

  • Simply Wall St.

    This QuidelOrtho Insider Increased Their Holding By 54% Last Year

    Viewing insider transactions for QuidelOrtho Corporation's ( NASDAQ:QDEL ) over the last year, we see that insiders...

  • Business Wire

    QuidelOrtho Receives FDA 510(k) Clearance for Its QuickVue® COVID-19 Test

    SAN DIEGO, April 02, 2024--QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho" or the "Company") has received U.S. Food and Drug Administration ("FDA") 510(k) clearance for its QuickVue COVID-19 test. This clearance allows the test to be used with accuracy and convenience in home and medical facility settings with CLIA certificates of waiver. This achievement also reflects QuidelOrtho’s dedication to delivering effective testing solutions while highlighting ongoing efforts in research and deve